CytoMed Therapeutics (GDTC) News Today $2.56 +0.12 (+4.92%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2.4% - Time to Sell?December 17, 2024 | americanbankingnews.comCytoMed Therapeutics Expands Leadership Amid Strategic GrowthDecember 5, 2024 | tipranks.comCytoMed Therapeutics Limited (GDTC)July 19, 2024 | finance.yahoo.comCytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid CancersJuly 17, 2024 | globenewswire.comCytoMed Therapeutics Ltd GDTCMarch 27, 2024 | morningstar.comCytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage RegenerationMarch 20, 2024 | finance.yahoo.comCYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | finanznachrichten.deCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | markets.businessinsider.comCytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision TherapiesMarch 18, 2024 | globenewswire.comCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairMarch 4, 2024 | globenewswire.comTrading was temporarily halted for "GDTC" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. February 7, 2024 | marketbeat.comTrading was temporarily halted for "GDTC" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | marketbeat.comCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyAugust 15, 2023 | finance.yahoo.comCytoMed Therapeutics Ltd (GDTC)August 8, 2023 | investing.comInsiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51mAugust 8, 2023 | finance.yahoo.comCytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comWhy Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?July 11, 2023 | investorplace.comTrading was temporarily halted for "GDTC" at 10:05 AM with a stated reason of "LULD pause."May 9, 2023 | marketbeat.comTrading was temporarily halted for "GDTC" at 10:05 AM with a stated reason of "LULD pause."May 9, 2023 | marketbeat.com Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. GDTC Media Mentions By Week GDTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GDTC News Sentiment▼0.000.61▲Average Medical News Sentiment GDTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GDTC Articles This Week▼10▲GDTC Articles Average Week Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LPTX News Today VERU News Today RGLS News Today MNOV News Today DERM News Today CNTX News Today ANRO News Today IMUX News Today PYXS News Today SKYE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GDTC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Go...ProsperityPub | SponsoredHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buyi...Insiders Exposed | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | Sponsored2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—wit...Darwin | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
